Kova-K

[Kova-K @KovaK6]

@damsel_jolly @HNohynek @THLorg https://t.co/TV0VSW7fE4

Halutaanko tätä Suomessa?

[Kova-K @KovaK6]

@HNohynek koska tutkitusti turvallisempi, perinteinen Covid- rokote #COVAXIN saadaan suomalaisille? #Covaxin4Kids

[Kova-K @KovaK6]

@RBobby215 @B1llyTh2K3d It is a rhetorical question. Therapies for blinding diseases are not related to eyewear markets.

[Kova-K @KovaK6]

@n8radcliffe Nasal and temporal sides are mixed up. It registered the wrong eye.

[Kova-K @KovaK6]

@Bonejones18 @HenryLodge2 @hsettymd So you are saying, that it is impossible to make the microneedle a bit longer? Longer than 1mm is included on the patent as well. Subretinal might not be better than SC, but as an in office procedure, this opens new possibilities. Did you even read the article?

[Kova-K @KovaK6]

@dsj1776 @Bio_Scout @AlexandriaCairo @jfais20 @HenryLodge2 @fezziwig2019 Time will tell

[Kova-K @KovaK6]

@dsj1776 @AlexandriaCairo @jfais20 @HenryLodge2 @fezziwig2019

$CLSD 's monopoly is over. This ones approval was published yesterday.

[Kova-K @KovaK6]

@Bio_Scout @dsj1776 @AlexandriaCairo @jfais20 @HenryLodge2 @fezziwig2019 Ever heard of leveraging with predicate devices?

[Kova-K @KovaK6]

@fezziwig2019 @Q319 They are gonna use it for Visudyne (verteporfin)

[Kova-K @KovaK6]

Repeating the question: since the manufacturing, QA, sales, marketing etc. will now be outsourced, why wouldn't the Xipere for $CLSD be approved?

[Kova-K @KovaK6]

Why wouldn't the Xipere for $CLSD be approved? It is more or less a modified triamcinolone, which is already widely used. The results from their trials have also been positive.